ETH
BLACR

Exos TFP Holdings’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Exos TFP Holdings’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$27K Hold
200,000
– – 0.02% 102
2023
Q3 		$46K Hold
200,000
– – 0.02% 118
2023
Q2 		$38.2K Buy
+200,000
New +$34.8K 0.02% 130

Other funds holding BLACR

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Exos TFP Holdings's BLACR Position: Q4 2023 in Review

Exos TFP Holdings held its Bellevue Life Sciences Acquisition Corp. Rights (BLACR) position steady in Q4 2023 at 200,000 shares worth $27K. The position accounts for 0.02% of the portfolio, ranked #102.

Exos TFP Holdings first reported a position in BLACR in Q2 2023 and has held it in 3 quarters since. The position peaked at $46K in Q3 2023. 28 funds tracked by Wall St. Rank hold BLACR as of Q4 2023.

  • Exos TFP Holdings held 200,000 shares of Bellevue Life Sciences Acquisition Corp. Rights worth $27K as of Q4 2023.
  • Exos TFP Holdings left its Bellevue Life Sciences Acquisition Corp. Rights share count unchanged in Q4 2023.
  • Bellevue Life Sciences Acquisition Corp. Rights made up 0.02% of Exos TFP Holdings's portfolio in Q4 2023, its #102 holding.
  • Exos TFP Holdings first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and has held it in 3 quarters since.
  • Exos TFP Holdings's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $46K in Q3 2023.
  • 28 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q4 2023.

Based on Exos TFP Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.